{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Autologous+CAR+Positive+T+cells", "query": { "intervention": "Autologous CAR Positive T cells" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Autologous+CAR+Positive+T+cells&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T02:59:35.804Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03500991", "title": "HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Central Nervous System Tumor, Pediatric", "Glioma", "Ependymoma", "Medulloblastoma", "Germ Cell Tumor", "Atypical Teratoid/Rhabdoid Tumor", "Primitive Neuroectodermal Tumor", "Choroid Plexus Carcinoma", "Pineoblastoma" ], "interventions": [ { "name": "HER2-specific chimeric antigen receptor (CAR) T cell", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "26 Years", "sex": "ALL", "summary": "1 Year to 26 Years" }, "enrollment_count": 10, "start_date": "2018-07-26", "completion_date": "2039-07-26", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-09-26T02:59:35.804Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03500991" }, { "nct_id": "NCT06413498", "title": "A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Anitocabtagene Autoleucel", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 452, "start_date": "2024-08-23", "completion_date": "2031-07", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-26T02:59:35.804Z", "location_count": 46, "location_summary": "Gilbert, Arizona • Duarte, California • Los Angeles, California + 35 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06413498" }, { "nct_id": "NCT03635632", "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Neuroblastoma", "Refractory Neuroblastoma", "Relapsed Osteosarcoma", "Relapsed Ewing Sarcoma", "Relapsed Rhabdomyosarcoma", "Uveal Melanoma", "Phyllodes Breast Tumor" ], "interventions": [ { "name": "C7R-GD2.CART cells", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "74 Years", "sex": "ALL", "summary": "1 Year to 74 Years" }, "enrollment_count": 94, "start_date": "2019-04-23", "completion_date": "2038-05-16", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-26T02:59:35.804Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03635632" }, { "nct_id": "NCT05274451", "title": "A Study to Investigate LYL797 in Adults With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "TNBC - Triple-Negative Breast Cancer", "Non-small Cell Lung Cancer", "Non Small Cell Lung Cancer", "Non Small Cell Lung Cancer Metastatic", "Non-Small Cell Carcinoma of Lung, TNM Stage 4", "Advanced Breast Cancer", "Advanced Lung Carcinoma", "NSCLC", "NSCLC, Recurrent", "NSCLC Stage IV", "Relapsed Cancer", "Relapse/Recurrence", "Recurrent Breast Cancer", "Recurrent NSCLC", "Platinum-resistant Ovarian Cancer", "Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Endometrial Cancer", "Endometrioid Tumor", "High Grade Serous Carcinoma", "Ovarian Epithelial Cancer" ], "interventions": [ { "name": "LYL797", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Lyell Immunopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2022-03-29", "completion_date": "2024-11-27", "has_results": false, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-09-26T02:59:35.804Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05274451" }, { "nct_id": "NCT03126864", "title": "Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematopoietic/Lymphoid Cancer", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "CD33-CAR-T Cell Infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "80 Years", "sex": "ALL", "summary": "1 Year to 80 Years" }, "enrollment_count": 11, "start_date": "2017-08-04", "completion_date": "2019-10-10", "has_results": false, "last_update_posted_date": "2019-11-04", "last_synced_at": "2026-09-26T02:59:35.804Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03126864" }, { "nct_id": "NCT04510051", "title": "CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Brain Neoplasm", "Recurrent Malignant Brain Neoplasm", "Refractory Malignant Brain Neoplasm" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "4 Years to 25 Years" }, "enrollment_count": 18, "start_date": "2020-12-04", "completion_date": "2027-02-24", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-09-26T02:59:35.804Z", "location_count": 3, "location_summary": "Duarte, California • Los Angeles, California • Ann Arbor, Michigan", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04510051" }, { "nct_id": "NCT04020575", "title": "Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells", "type": "BIOLOGICAL" }, { "name": "huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Minerva Biotechnologies Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2020-01-15", "completion_date": "2035-01-15", "has_results": false, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-09-26T02:59:35.804Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04020575" }, { "nct_id": "NCT06055439", "title": "A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroendocrine Tumors", "Colorectal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "CHM-2101 CAR-T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Chimeric Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 135, "start_date": "2024-05-15", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-09-26T02:59:35.804Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06055439" }, { "nct_id": "NCT00881920", "title": "Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Myeloma", "Leukemia" ], "interventions": [ { "name": "Kappa CD28 T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2009-07", "completion_date": "2035-07", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-09-26T02:59:35.804Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00881920" }, { "nct_id": "NCT05627323", "title": "CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme of Brain" ], "interventions": [ { "name": "CHM-1101 CAR-T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Chimeric Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2023-06-06", "completion_date": "2026-05-29", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-09-26T02:59:35.804Z", "location_count": 2, "location_summary": "Duarte, California • Austin, Texas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05627323" } ] }